Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies

Inclusion Criteria: * Age ≥ 18 years. * Histopathologically confirmed diagnosis of a metastatic non-hematologic malignancy. * ECOG (Eastern Cooperative Oncology Group) performance status of ≤ 2 * Adequate renal function * Adequate hepatic function (total bilirubin ≤ 1.5x ULN (upper limit of normal) for the institution; AST \[aspartate transaminase\] and ALT \[alanine transaminase\] ≤ 3x ULN, or ≤ 5x ULN if due to liver involvement by tumor). * Adequate bone marrow function (hemoglobin ≥ 9.0 g/dL; unsupported platelets ≥ 100 x10 9 cells/L; absolute neutrophil count ≥ 1.5x10 9 cells/L * Corrected QT interval (QTc) \< 470 ms * Subjects must have at least one tumor lesion that is suitable for repeat biopsy, and must agree to two tumor biopsies (pre- and post- treatment). * Willing and able to participate in the trial and comply with all trial requirements. Exclusion Criteria: * Gastrointestinal (GI) condition which could interfere with the swallowing or absorption of study medication. * Uncontrolled or severe concurrent medical condition (including uncontrolled brain metastases). * History of upper gastrointestinal bleeding, ulceration, or perforation within 12 months. * Known history of stroke or cerebrovascular accident within 6 months. * Subjects being actively treated for a secondary malignancy.